Kalaris Therapeutics Inc

NASDAQ:KLRS

Biotechnology

Healthcare
$2.30 +3.52%

+$0.16 today

Market cap
$54.75M
Beta
0.14
P/E (TTM)
-2.5
EPS (TTM)
-$1.86
52W Low $2.14High $11.88

Volume 0.07M

Average 0.08M

Cash Flow

Check whether earnings turn into cash.

Operating Cash Flow

-$42.98M

FY 2025 · Annual

Investing Cash Flow

-$19.72M

FY 2025 · Annual

Financing Cash Flow

$159.61M

FY 2025 · Annual

+759961.9% YoY

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(171.96M)(15.49M)(14.7M)(58.77M)(43.44M)
Depreciation & Amortization1.12M00013K
Deferred Income Tax00000
Stock-Based Compensation0271K148K00
Change in Working Capital19.35M3.4M(1.09M)(25.31M)3.43M
Accounts Receivables400K00206K0
Inventory00000
Accounts Payables20.29M1.83M(402K)(28.86M)(88K)
Other Working Capital(1.34M)1.57M(690K)3.35M3.52M
Other Non-Cash Items45.17M2.04M1.51M16.37M(2.98M)
Operating Cash Flow(106.32M)(9.78M)(14.13M)(67.71M)(42.98M)
Capital Expenditures(26K)000(200K)
Acquisitions (Net)00000
Purchases of Investments(76.59M)000(34.52M)
Sales of Investments262.6M0095M15M
Other Investing Activities00000
Investing Cash Flow185.98M0095M(19.72M)
Debt Repayment04.3M6M07.5M
Common Stock Issued232K0021K50M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities05K1.5M0102.11M
Financing Cash Flow232K12.78M14.24M21K159.61M
Effect of Forex Changes(896K)00852K(117.15M)
Net Change in Cash79M3M110K28.17M(20.24M)
Free Cash Flow(106.35M)(9.78M)(14.13M)(67.71M)(43.18M)

Free Cash Flow

Net Income to FCF bridge

FY2025

= Net Income-$43.4M
+ D&A$13.0K
+ Stock-Based Comp$0
+ Deferred Tax$0
+ Working Capital$3.4M
- Other Non-Cash-$3.0M
= Operating Cash Flow-$43.0M
- Capex-$200.0K
= Free Cash Flow-$43.2M

Analysis

FY2025 free cash flow is -$43.2M. FCF conversion is 99.4% of net income. Operating cash flow was -$43.0M, with capex of -$200.0K. The largest bridge item is Working Capital at $3.4M.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
SC 13GSC 13G filingOct 26, 2026

Does KLRS generate free cash flow?

Kalaris Therapeutics Inc (KLRS) generated -$43.18M of free cash flow in fiscal 2025.

How much operating cash flow does KLRS produce?

Operating cash flow was -$42.98M, before capital expenditures of $200,000.00.